MARKET

AMLX

AMLX

Amylyx Pharmaceuticals
NASDAQ
14.88
+0.15
+1.02%
Pre Market: 14.90 +0.02 +0.13% 08:55 05/12 EDT
OPEN
14.84
PREV CLOSE
14.73
HIGH
15.23
LOW
14.70
VOLUME
3.02K
TURNOVER
0
52 WEEK HIGH
18.61
52 WEEK LOW
4.200
MARKET CAP
1.65B
P/E (TTM)
-9.8759
1D
5D
1M
3M
1Y
5Y
1D
Is It Too Late To Consider Amylyx Pharmaceuticals (AMLX) After A 220% One Year Surge?
Simply Wall St · 20h ago
FDA's Makary On Brink: Why Biotech And Pharma Investors Shouldn't Panic (Or Celebrate)
Seeking Alpha · 23h ago
Analysts Have Conflicting Sentiments on These Healthcare Companies: Amylyx Pharmaceuticals Inc (AMLX), Hims & Hers Health (HIMS) and MBX Biosciences, Inc. (MBX)
TipRanks · 1d ago
Amylyx Pharmaceuticals Inc (AMLX) Receives a Buy from Guggenheim
TipRanks · 1d ago
Weekly Report: what happened at AMLX last week (0504-0508)?
Weekly Report · 1d ago
Analysts Offer Insights on Healthcare Companies: Amylyx Pharmaceuticals Inc (AMLX), BioAge Labs, Inc. (BIOA) and Pharvaris (PHVS)
TipRanks · 1d ago
Amylyx Readies Avexitide For PBH With Pivotal Trial And Valuation Gap
Simply Wall St · 2d ago
Amylyx Pharmaceuticals Charts Path to 2026 Trial Data
TipRanks · 3d ago
More
About AMLX
Amylyx Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on four investigational therapies across several diseases. Its lead investigational asset is avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist. Avexitide has been evaluated as a treatment for Post-Bariatric Hypoglycemia (PBH) and congenital HI, two indications characterized by hyperinsulinemic hypoglycemia. In addition to avexitide, it is advancing AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol in Wolfram syndrome, AMX0114 in amyotrophic lateral sclerosis (ALS), and AMX0318 in PBH and other rare diseases. AMX0035 is designed to mitigate neurodegeneration by targeting endoplasmic reticulum stress and mitochondrial dysfunction, two cellular processes central to neuronal cell death and neurodegeneration. AMX0114 is an investigational antisense oligonucleotide and AMX0318 is a novel GLP-1 receptor antagonist.

Webull offers Amylyx Pharmaceuticals Inc stock information, including NASDAQ: AMLX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AMLX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AMLX stock methods without spending real money on the virtual paper trading platform.